PR1 Leukemia Peptide Vaccine
DCTPepD ID DCTPepD0097
Active Ingredients PR1 Leukemia Peptide Vaccine
Description A cancer vaccine containing PR1, a 9 amino-acid human leukocyte antigen (HLA)-A2 restricted peptide derived from proteinase 3, with potential immunotherapeutic activity. Vaccination with PR1 leukemia peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing proteinase 3, resulting in tumor cell lysis. Often overexpressed in leukemic cells, proteinase 3 is a serine proteinase that activates progelatinase A and is involved in angiogenesis and metastasis.
Synonyms PR1: 169-177; Leukemia Peptide Vaccine, PR1; PR1 Leukemia Peptide Vaccine; Proteinase 3:PR1 Peptide
Disease Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome
Classification
Peptide and derivative Vaccine
Structure Information
Molecular Formula C45H79N11O15
Molecular Weight 1014.2
Active Sequence VLQELNVTV
Sequence Length 9
Modification None
IUPAC Name (4S)-4-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S,3R)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
InChI InChI=1S/C45H79N11O15/c1-19(2)16-27(40(65)52-29(18-31(47)59)41(66)54-34(22(7)8)43(68)56-36(24(11)57)44(69)55-35(23(9)10)45(70)71)51-38(63)26(13-15-32(60)61)49-37(62)25(12-14-30(46)58)50-39(64)28(17-20(3)4)53-42(67)33(48)21(5)6/h19-29,33-36,57H,12-18,48H2,1-11H3,(H2,46,58)(H2,47,59)(H,49,62)(H,50,64)(H,51,63)(H,52,65)(H,53,67)(H,54,66)(H,55,69)(H,56,68)(H,60,61)(H,70,71)/t24-,25+,26+,27+,28+,29+,33+,34+,35+,36+/m1/s1
InChI_Key WOACUGNMTZAEJZ-GXLXRQKGSA-N
SMILES CC(C[C@@H](C(N[C@H](C(N[C@@H](C(C)C)C(N[C@@H]([C@H](O)C)C(N[C@@H](C(C)C)C(O)=O)=O)=O)=O)CC(N)=O)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](C(C)C)N)=O)CC(C)C)=O)CCC(N)=O)=O)CCC(O)=O)=O)C
External Codes
PubChem CID 11672494
DrugBank Accession Number DB15276
NCI Thesaurus Code C2235
UNII 54XUF2TZ7G GSRS
CAS 182253-77-6
Drug approval
Drug indication
Investigated for use/treatment in Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome.
The drug is not approved.
ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
---|---|---|---|---|
NCT00488592 | Efficacy of Peptide (WT1) and Peptide(PRI) Vaccination for Patients With Low Risk Myeloid Malignancies | Myelodysplastic Syndrome (MDS); Acute Myeloid Leukemia (AML); Chronic Myeloid Leukemia (CML) | Phase 2 | Treatment |
NCT00004918 | A Phase I/II Study of PR1 (NSC 698102) Human Leukemia Peptide Vaccine With Montanide ISA 51 (NSC 675756) or Montanide ISA 51 VG (NSC 737063) Adjuvant | Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Myeloid Leukemia in Remission; Chronic Phase Chronic Myelogenous Leukemia; Previously Treated Myelodysplastic Syndromes; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Relapsing Chronic Myelogenous Leukemia | Phase 1/2 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.